Publications by authors named "Atefeh Biabangard"
Validation of Exotoxin A Domain I Interaction with the Novel Human scFv Antibody.
Infect Disord Drug Targets
July 2023
Background: Pseudomonas (P.) aeruginosa is one of the leading causes of nosocomial infections. The pathogenicity of P.
View Article and Find Full Text PDFCurrently, liposomes have emerged as efficient and safer nano-carriers for targeted therapy in different cancers. This work aimed to employ PEGylated liposomal doxorubicin (Doxil®/PLD), modified with AR13 peptide, to target Muc1 on the surface of colon cancerous cells. We performed molecular docking and simulation studies (using Gromacs package) of AR13 peptide against Muc1 to analyze and visualize the peptide-Muc1 binding combination.
View Article and Find Full Text PDFArticle Synopsis
- This study looked for a better way to target cancer treatments to specific cells by using a special peptide called FA12.
- Researchers created a new type of liposome (a tiny bubble) filled with a medicine called doxorubicin and added the FA12 peptide to it.
- The results showed that this new treatment method was more effective in attacking cancer cells and helped mice with cancer live longer compared to other treatments.
Immunoinformatics Approach to Design a Novel Subunit Vaccine Against Visceral Leishmaniasis.
Int J Pept Res Ther
December 2021
Visceral leishmaniasis (VL) infection is mostly caused by and affects countries worldwide. Despite the need for a safe and effective vaccine against leishmaniasis due to the increased drug resistance, however, no vaccine has yet been licensed for clinical use. This study revolves around the immunoinformatics approach to design a multi-epitope vaccine against VL infection.
View Article and Find Full Text PDF